Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma

RMAT Designation Follows Positive Data from ALLO-501A ALPHA2 Trial in Heavily Pretreated Patients with Relapsed or Refractory Large B cell Lymphoma (LBCL) Data Presented at the American Society of Hematology…

Continue ReadingAllogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma

Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Cells Derived from Healthy, Younger Donors were More Abundant with Greater Fitness and Cancer Killing Potential Than Cells Derived from Patients with Cancer Findings Underscore Potential of Allogeneic CAR T…

Continue ReadingAllogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal

Allogeneic CAR T Pioneer Highest Ranked Bay Area Biotech in the Large Company Category Based on Employee Survey SOUTH SAN FRANCISCO, Calif. , May 09, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics,…

Continue ReadingAllogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal

Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma

ODD Follows FDA Fast Track Designation Granted for ALLO-605 in Q2 2021 ALLO-605 is in Phase 1 in the IGNITE Trial and Part of Allogene’s Multi-Pronged Strategy Targeting BCMA BCMA…

Continue ReadingAllogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma

Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products

Interactive Experience Designed to Showcase the 136,000sf cGMP Facility Located in Newark, California Cell Forge 1 is Operational in Preparation for the Company’s First Pivotal Trial with ALLO-501A for the…

Continue ReadingAllogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products

Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal

Data Continue to Highlight the Potential of ALLO-316 to Treat Both Solid Tumors and Hematologic Malignancies ALLO-316, in Phase 1 TRAVERSE Trial for the Treatment of Renal Cell Carcinoma, Granted…

Continue ReadingAllogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal